Resveratrol as cardioprotective agent: Evidence from bench and bedside

Resveratrol in Health and Disease

Volumn , Issue , 2005, Pages 539-556

  Burjonroppa, Sukesh ^a   Fujise, Ken ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954102352     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420026474     Document Type: Chapter

References (78)

1. Braunwald E, Shattuck lecture. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities, N Engl J Med 337, 1360-1369, 1997.
2. WOSCOPS Study Group, Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study, Am J Cardiol 76, 485-491, 1995.
3. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, and de Cani JS, Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), Circulation 101, 477-484, 2000.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 344, 1383-1389, 1994.
5. Tonkin AM, Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S), Am J Cardiol 76, 107C-112C, 1995.
6. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, and DeMaria AN, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial, JAMA 291, 1071-1080, 2004.
7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, and Skene AM, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med 350, 1495-1504, 2004.
8. Blake GJ and Ridker PM, Novel clinical markers of vascular wall inflammation, Circulation Res 89, 763-771, 2001.
9. Ridker PM, Clinical application of C-reactive protein for cardiovascular disease detection and prevention, Circulation 107, 363-369, 2003.
10. Sessa R, Di Pietro M, Santino I, del Piano M, Varveri A, Dagianti A, and Penco M, Chlamydia pneumoniae infection and atherosclerotic coronary disease, Am Heart J 137, 1116-1119, 1999.
11. McCully KS, Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis, Am J Pathol 56, 111-128, 1969.
12. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, and Graham I, Hyperhomocysteinemia: an independent risk factor for vascular disease, N Engl J Med 324, 1149-1155, 1991.
13. Lenhart SE and Nappi JM, Vitamins for the management of cardiovascular disease: a simple solution to a complex problem?, Pharmacotherapy 19, 1400-1414, 1999.
14. Kris-Etherton P, Eckel RH, Howard BV, St Jeor S, and Bazzarre TL, AHA Science Advisory: Lyon Diet Heart Study benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I dietary pattern on cardiovascular disease, Circulation 103, 1823-1825, 2001.
15. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, and Mamelle N, Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study, Circulation 99, 779-785, 1999.
16. Leaf A, Dietary prevention of coronary heart disease: the Lyon Diet Heart Study, Circulation 99, 733-735, 1999.
17. de Lorgeril M, Salen P, Caillat-Vallet E, Hanauer MT, Barthelemy JC, and Mamelle N, Control of bias in dietary trial to prevent coronary recurrences: the Lyon Diet Heart Study, Eur J Clin Nutr 51, 116-122, 1997.
18. St Leger AS, Cochrane AL, and Moore F, Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine, Lancet 1, 1017-1020, 1979.
19. Renaud S and de Lorgeril M, Wine, alcohol, platelets, and the French paradox for coronary heart disease, Lancet 339, 1523-1526, 1992.
20. Hegsted DM and Ausman LM, Diet, alcohol and coronary heart disease in men, J Nutr 118, 1184-1189, 1988.
21. Criqui MH and Ringel BL, Does diet or alcohol explain the French paradox?, Lancet 344, 1719-1723, 1994.
22. Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M, and Bertelli A, Antiplatelet activity of synthetic and natural resveratrol in red wine, Int J Tissue React 17, 1-3, 1995.
23. Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA, Jr., Stampfer MJ, Willett WC, and Rimm EB, Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men, N Engl J Med 348, 109-118, 2003.
24. Sandler M and Pinder R, Wine: A Scientific Exploration, Taylor and Francis, New York, 2002.
25. Balkau B, Eschwege F, and Eschwege E, Ischemic heart disease and alcoholrelated causes of death: a view of the French paradox, Ann Epidemiol 7, 490-497, 1997.
26. Nanji AA, Alcohol and ischemic heart disease: wine, beer or both?, Int J Cardiol 8, 487-489, 1985.
27. Nanji AA and French SW, Alcoholic beverages and coronary heart disease, Atherosclerosis 60, 197-198, 1986.
28. Renaud S and de Lorgeril M, The French paradox: dietary factors and cigarette smoking-related health risks, Ann NY Acad Sci 686, 299-309, 1993.
29. Ulbricht TL and Southgate DA, Coronary heart disease: seven dietary factors, Lancet 338, 985-992, 1991.
30. Tuomilehto J and Kuulasmaa K, WHO MONICA Project: assessing CHD mortality and morbidity, Int J Epidemiol 18, S38-S45, 1989.
31. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, and Pajak A, Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents, Circulation 90, 583-612, 1994.
32. Ducimetiere R and Richard J, Dietary lipids and coronary heart disease. Is there a French paradox?, Nutr Metab Cardioivasc Dis 2, 195-201, 1992.
33. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, and Pezzuto JM, Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, Science 275, 218-220, 1997.
34. Bertelli A, Bertelli AA, Gozzini A, and Giovannini L, Plasma and tissue resveratrol concentrations and pharmacological activity, Drugs Exp Clin Res 24, 133-138, 1998.
35. Fuhrman B, Lavy A, and Aviram M, Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation, Am J Clin Nutr 61, 549-554, 1995.
36. Hung LM, Su MJ, Chu WK, Chiao CW, Chan WF, and Chen JK, The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy, Br J Pharmacol 135, 1627-1633, 2002.
37. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, and Witztum JL, Autoantibody against oxidised LDL and progression of carotid atherosclerosis, Lancet 339, 883-887, 1992.
38. Salonen RM, Nyyssonen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH, Tuomainen TP, Valkonen VP, Ristonmaa U, Lakka HM, Vanharanta M, Salonen JT, and Poulsen HE, Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study, Circulation 107, 947-953, 2003.
39. Liu MW, Roubin GS, and King SB III, Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia, Circulation 79, 1374-1387, 1989.
40. Gravanis MB and Roubin GS, Histopathologic phenomena at the site of percutaneous transluminal coronary angioplasty: the problem of restenosis, Hum Pathol 20, 477-485, 1989.
41. Zou J, Huang Y, Cao K, Yang G, Yin H, Len J, Hsieh TC, and Wu JM, Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model, Life Sci 68, 153-163, 2000.
42. Mnjoyan ZH and Fujise K, Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: a role of p53-p21(WAF1/CIP1) pathway, Biochem Biophys Res Commun 311, 546-552, 2003.
43. Clowes AW, Reidy MA, and Clowes MM, Mechanisms of stenosis after arterial injury, Lab Invest 49, 208-215, 1983.
44. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, and Dzau VJ, Antisense oligonucleotides directed at cell cycle regulatory genes as strategy for restenosis therapy, Trans Assoc Am Physicians 106, 54-61, 1993.
45. Jackson CL and Schwartz SM, Pharmacology of smooth muscle cell replication, Hypertension 20, 713-736, 1992.
46. Braun-Dullaeus RC, Mann MJ, and Dzau VJ, Cell cycle progression:new therapeutic target for vascular proliferative disease, Circulation 98, 82-89, 1998.
47. Wang Z, Huang Y, Zou J, Cao K, Xu Y, and Wu JM, Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro, Int J Mol Med 9, 77-79, 2002.
48. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, and Goldberg DM, The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease, Clin Chim Acta 235, 207-219, 1995.
49. Kirk RI, Deitch JA, Wu JM, and Lerea KM, Resveratrol decreases early signaling events in washed platelets but has little effect on platalet in whole food, Blood Cells Mol Dis 26, 144-150, 2000.
50. Orallo F, Alvarez E, Camina M, Leiro JM, Gomez E, and Fernandez P, The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption, Mol Pharmacol 61, 294-302, 2002.
51. Imamura G, Bertelli AA, Bertelli A, Otani H, Maulik N, and Das DK, Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice, Am J Physiol Heart Circ Physiol 282, H1996-H2003, 2002.
52. Giovannini L, Migliori M, Longoni BM, Das DK, Bertelli AA, Panichi V, Filippi C, and Bertelli A, Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys, J Cardiovasc Pharmacol 37, 262-270, 2001.
53. Kawashima S and Yokoyama M, Dysfunction of endothelial nitric oxide synthase and atherosclerosis, Arterioscler Thromb Vasc Biol 24, 998-1005, 2004.
54. Klurfeld DM and Kritchevsky D, Differential effects of alcoholic beverages on experimental atherosclerosis in rabbits, Exp Mol Pathol 34, 62-71, 1981.
55. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, Elis A, and Aviram M, Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation, Arterioscler Thromb Vasc Biol 17, 2744-2752, 1997.
56. Vinson JA, Teufel K, and Wu N, Red wine, dealcoholized red wine, and especially grape juice, inhibit atherosclerosis in a hamster model, Atherosclerosis 156, 67-72, 2001.
57. Sargent CA, Liu EC, Chao CC, Monshizadegan H, Webb ML, and Grover GJ, Role of endothelin receptor subtype B (ET-B) in myocardial ischemia, Life Sci 55, 1833-1844, 1994.
58. Tonnessen T, Giaid A, Saleh D, Naess PA, Yanagisawa M, and Christensen G, Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia, Circulation Res 76, 767-772, 1995.
59. Liu JC, Chen JJ, Chan P, Cheng CF, and Cheng TH, Inhibition of cyclic straininduced endothelin-1 gene expression by resveratrol, Hypertension 42, 1198-1205, 2003.
60. Corder R, Douthwaite JA, Lees DM, Khan NQ, Viseu Dos Santos AC, Wood EG, and Carrier MJ, Endothelin-1 synthesis reduced by red wine, Nature 414, 863-864, 2001.
61. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, and Burnett JC Jr, Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis, N Engl J Med 325, 997-1001, 1991.
62. Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, and Loeffler BM, Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis, Circulation 104, 864-869, 2001.
63. Zeiher AM, Goebel H, Schachinger V, and Ihling C, Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina, Circulation 91, 941-947, 1995.
64. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, and Yazaki Y, Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells, FEBS Lett 238, 249-252, 1988.
65. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, and Nemerson Y, Tissue factor in the pathogenesis of atherosclerosis, Thromb Haemost 78, 200-204, 1997.
66. Rapaport SI and Rao LV, The tissue factor pathway: how it has become a “prima ballerina’', Thromb Haemost 74, 7-17, 1995.
67. Pendurthi UR, Williams JT, and Rao LV, Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: a possible mechanism for the cardiovascular benefits associated with moderate consumption of wine, Arterioscler Thromb Vasc Biol 19, 419-426, 1999.
68. Fleck RA, Rao LV, Rapaport SI, and Varki N, Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody, Thromb Res 59, 421-437, 1990.
69. Drake TA, Ruf W, Morrissey JH, and Edgington TS, Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line, J Cell Biol 109, 389-395, 1989.
70. Wilcox JN, Smith KM, Schwartz SM, and Gordon D, Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque, Proc Natl Acad Sci USA 86, 2839-2843, 1989.
71. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, and Fallon JT, In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X, Lab Invest 75, 451-461, 1996.
72. Gehm BD, McAndrews JM, Chien PY, and Jameson JL, Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor, Proc Natl Acad Sci USA 94, 14138-14143, 1997.
73. Gehm BD, Levenson AS, Liu H, Lee EJ, Amundsen BM, Cushman M, Jordan VC, and Jameson JL, Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2, J Steroid Biochem Mol Biol 88, 223-234, 2004.
74. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, and Cushman M, Estrogen plus progestin and the risk of coronary heart disease, N Engl J Med 349, 523-534, 2003.
75. Haider UG, Sorescu D, Griendling KK, Vollmar AM, and Dirsch VM, Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells, Mol Pharmacol 63, 925-932, 2003.
76. George SJ, Angelini GD, Capogrossi MC, and Baker AH, Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis, Gene Ther 8, 668-676, 2001.
77. Guevara NV, Kim HS, Antonova EI, and Chan L, The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo, Nat Med 5, 335-339, 1999.
78. Merched AJ, Williams E, and Chan L, Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling, Arterioscler Thromb Vasc Biol 23, 1608-1614, 2003.